ERBB2 and cancer: These findings underscore that CD47 and αvβ3 coexpression is not a pan‐cancer phenomenon, but rather selectively enriched in particular malignancies—most notably in triple‐negative breast cancers (TNBC, ER−/PR−/HER2−) such as MDA‐MB‐231, Hs578T, and MDA‐MB‐468.[41, 42]